PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN

Related Experiment Video

Updated: Oct 27, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.1K

Yifei Qin1, Qiang Zuo1,2, Lei Huang1

  • 1Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

NPJ Precision Oncology
|July 20, 2021
PubMed

Insights

Targeting PERK offers a new strategy against BRAF inhibitor-resistant melanoma, especially in tumors with PTEN deficiency. This approach aims to overcome acquired resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • BRAF inhibitors are effective first-line melanoma treatments, but acquired resistance leads to recurrence.
  • Emerging resistance mechanisms necessitate novel therapeutic targets beyond BRAF.
  • PTEN status influences treatment efficacy and resistance pathways in melanoma.

Purpose of the Study:

  • To investigate the role of PERK in BRAF inhibitor-acquired resistance in melanoma.
  • To evaluate PERK inhibition as a therapeutic strategy for BRAF inhibitor-resistant melanoma, particularly in PTEN-deficient cases.

Main Methods:

  • Utilized shRNA and pharmacological inhibitors to target PERK.
  • Assessed the efficacy of PERK inhibition in vitro and in vivo models of BRAF inhibitor-resistant melanoma with impaired PTEN.

Main Results:

  • PERK was identified as critical in acquired resistance to BRAF inhibitors in PTEN-deficient melanoma.
  • Inhibition of PERK effectively blocked the growth of resistant melanoma cells both in vitro and in vivo.
  • Findings complement previous work on the AXL/AKT axis in PTEN-wild-type resistance.

Conclusions:

  • PERK inhibition presents a promising therapeutic strategy for BRAF mutant melanoma with PTEN deficiency and acquired resistance.
  • Understanding PTEN status is crucial for developing targeted resistance-combating strategies in melanoma.
  • This research provides new insights for overcoming BRAF inhibitor resistance in diverse melanoma subtypes.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.1K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K